Thermo Fisher Scientific announced an expansion plan with its strategic partnership with Sanofi that will enable additional US drug product manufacturing. The terms of the deal have not been disclosed yet increasing the US drug manufacturing capacity.
Under the agreement, Thermo Fisher will acquire Sanofi’s sterile manufacturing site in Ridgefield, New Jersey, and will continue to manufacture a portfolio of therapies for Sanofi. In addition, Thermo Fisher will increase the utilization of the site so that to meet the increasing demand from biotech and pharma customers for US drug manufacturing capacity. The Ridgefield site is a state-of-the-art sterile fill-finish and packaging facility. Sanofi’s Ridgefield site has a world-class team of more than 200 employees that will further join the Thermo Fisher once the transaction is completed.
“Sanofi’s Ridgefield site will strengthen our US manufacturing capabilities, enabling us to better support our pharmaceutical and biotech customers with the critical production capacity needed for essential medicines,” said Marc N. Casper, Chairman, President and CEO of Thermo Fisher. “We will also expand and further strengthen our long-standing partnership with Sanofi, while investing to bring additional capacity and enhanced capabilities at this site. We look forward to welcoming all Ridgefield employees to Thermo Fisher later this year.”
Brendan O’Callaghan, Global Head of Manufacturing & Supply, Sanofi, added, “This expansion of our long-term partnership with Thermo Fisher will help ensure a continued supply of high-quality Sanofi products, maintaining our commitment to American manufacturing and supporting our customers and patients in the US, while enabling the future development and growth of the site.”
Thermo Fisher operates a leading global sterile fill-finish manufacturing network. The company has sites in US in locations including Greenville, North Carolina, and Plainville, Massachusetts. These sites are significant to the company’s Accelerator Drug Development 360° CDMO and CRO solutions, revolutionizing the pharmaceutical value chain for early-stage biotech and biopharma firms to accelerate life-changing medicines to patients.
The transaction is expected to be completed in the second half of 2025, that is subject to customary closing conditions. The completion of this process will make Sanofi’s Ridgefield facility a part of Thermo Fisher’s pharma services business that falls under the Laboratory Products and Biopharma Services segment.
